Sunil Saini

Sunil Saini

Auto-generated profile, based on publicly available information

Sunil Saini

Swami Rama Himalayan Univ, Canc Res Inst, Dept Surg Oncol, Dehra Dun 248140, Uttarakhand, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
DSDeivendran Sankaran
Deivendran Sankaran
ARAmjesh Revikumar
Amjesh Revikumar
APASWATHY MARY PAUL
ASWATHY MARY PAUL
BGBijesh George
Bijesh George
RKRajat Kala
Rajat Kala
RKRAKESH KUMAR
RAKESH KUMAR
Over the last three decades, p21-activated kinases (PAKs) have emerged as prominent intracellular nodular signaling molecules in cancer cells with a spectrum of cancer-promoting functions ranging from cell survival to anchorage-independent growth to cellular invasiveness. As PAK family members are widely overexpressed and/or hyperactivated in a variety of human tumors, over the years PAKs have also emerged as therapeutic targets, resulting in the development of clinically relevant PAK inhibitors. Over the last two decades, this has been a promising area of active investigation for several academic and pharmaceutical groups. Similar to other kinases, blocking the activity of one PAK family member leads to compensatory activity on the part of other family members. Because PAKs are also activated by stress-causing anticancer drugs, PAKs are components in the rewiring of survival pathways in the action of several therapeutic agents; in turn, they contribute to the development of therapeutic resistance. This, in turn, creates an opportunity to co-target the PAKs to achieve a superior anticancer cellular effect. Here we discuss the role of PAKs and their effector pathways in the modulation of cellular susceptibility to cancer therapeutic agents and therapeutic resistance.

1 May 2024 in Journal of Clinical and Diagnostic Research
Verified
Journal Article
Closed access
RKRajat Kala
Rajat Kala
SSSunil Saini
Sunil Saini
PRPartha Roy
Partha Roy
MGMeenu Gupta
Meenu Gupta
VKViney Kumar
Viney Kumar
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.

1 February 2024 in Journal of Clinical and Diagnostic Research
Verified
Journal Article
Closed access
SSShivangi Sundram
Shivangi Sundram
AAAnshika Arora
Anshika Arora
SNSourabh Nandi
Sourabh Nandi
SSSunil Saini
Sunil Saini
Introduction: Tongue carcinoma presents a global oncological challenge due to its aggressive nature and late-stage diagnosis. Glossectomy, a key surgical procedure for advanced cases, significantly affects both cancer control and essential functions such as speech and swallowing. Aim: To analyse the impact of different glossectomy types on oncological and functional outcomes in patients with advanced carcinoma of the tongue. Materials and Methods: A cross-sectional study was conducted in the Department of Surgical Oncology, Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Uttarakhand, India over a one-year period from September 1, 2022, to August 31, 2023. The study included 47 patients with squamous cell carcinoma of the oral and posterior tongue who underwent glossectomy. Oncological outcomes (mortality and hospital stay) and functional outcomes (swallowing, speech, dysphagia, and Quality of Life (QoL)) were assessed. The questionnaires used were the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30), EORTC questionnaire for the assessment of QoL in head and neck cancer patients (EORTC QLQ-H&N35), M.D. Anderson Dysphagia Inventory (MDADI), and Speech Handicap Index (SHI). Follow-up was conducted at the 6th week to assess changes in the functional aspects compared to the baseline scores. Data were entered into Microsoft Excel, and the analysis was performed using Statistical Packages for Social Sciences (SPSS) software version 25.0. The data were analysed using the Wilcoxon Signed Rank test. A p-value of <0.05 was considered statistically significant. Results: The study comprised 37 (78.72%) males and 10 (21.28%) females, with a mean age of 47.77±12.6 years. Preoperative staging indicated that 22 (46.81%) patients had T2N0 stage, 16 (34.04%) patients had T3, and 9 (19.15%) patients had T4a disease. Among the patients, 14 (29.79%) underwent partial glossectomy, 27 (57.45%) underwent hemiglossectomy, and 3 (6.38%) underwent subtotal glossectomy, and 3 (6.38%) underwent total glossectomy. The mean duration of hospital stay was 10.09±2.87 days. There were no instances of mortality or tumour recurrence at the 6th week. Regarding the functional outcomes, compared to baseline, at the 6th week, there was a significant decrease in EORTC QLQ-H&N35 median scores from 6.94 to 1.73 (p=0.005), but no significant change in the mean EORTC QLQ-C30 (90±8.22 versus (vs) 89.72±8.52, p=0.368), mean MDADI (4.51±1.2 vs 4.43±1.19, p=0.585), and mean SHI (15.81±25.76 vs 13.43±26.19, p=0.052). Conclusion: It can be inferred that glossectomy for advanced carcinoma of the tongue leads to a significant improvement in symptoms; however, the overall Quality of Life (QoL) and functions of the tongue such as swallowing and speech remain comparable to pre-surgery levels.

14 January 2024 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
SSShivangi Sundram
Shivangi Sundram
SNSourabh Nandi
Sourabh Nandi
AAAnshika Arora
Anshika Arora
SSSunil Saini
Sunil Saini

16 April 2024 in Indian Journal of Otolaryngology and Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
CMChiranjit Mukherjee
Chiranjit Mukherjee
AAAnshika Arora
Anshika Arora
SNSourabh Nandi
Sourabh Nandi
SSSunil Saini
Sunil Saini

17 November 2023 in Research Square
Verified
Preprint
Open access
PDF file
CMChiranjit Mukherjee
Chiranjit Mukherjee
SNSourabh Nandi
Sourabh Nandi
AAAnshika Arora
Anshika Arora
SSSunil Saini
Sunil Saini
MGMeenu Gupta
Meenu Gupta
SSShivangi Sundram
Shivangi Sundram
Esophageal cancer poses a significant global health burden, characterized by high aggressiveness and mortality rates. Despite a decline in overall incidence, certain regions exhibit a rise of adenocarcinoma incidence. At present multimodality approach with neoadjuvant treatment (Chemotherapy, Radiotherapy or both) followed by surgery with or without adjuvant treatment is standard of care, although there is no standard protocol. This retrospective, conducted at a tertiary center in the Himalayan region, explores the outcomes of esophageal and gastroesophageal junctional cancer patients undergoing surgery following neoadjuvant chemotherapy. Among 106 patients, 87 received preoperative chemotherapy, with demographic data revealing a male predominance and prevalent squamous cell carcinoma histology. Neoadjuvant therapy mainly comprised taxane-platinum regimens, with subsequent surgical procedures predominantly Ivor Lewis or McKeown esophagectomies. 30-day morbidity and mortality were observed in 35.29% of cases, with nonsurgical complications, particularly respiratory issues, being the most common. Our study reported a complete pathological response in 12.5% cases and an R0 resection rate exceeding 93%. While acknowledging the study’s retrospective and non-randomized nature, these findings suggest that neoadjuvant chemotherapy facilitates safe esophageal cancer surgeries specifically in undernourished patients.